Zobrazeno 1 - 10
of 42
pro vyhledávání: '"N. A. Simonian"'
Autor:
N. V. Zabolotskikh, E. Y. Vyrodova, A. O. Dorosheva, M. A. Semerdzhian, N. E. Simonian, M. V. Shamaeva, A. R. Artyushkova
Publikováno v:
Кубанский научный медицинский вестник, Vol 27, Iss 6, Pp 109-122 (2020)
Background. Mental and physical health of students is directly linked to the emotional safety of educational environment and its recent transformation. Adoption of distance learning and IT innovations in educational practice influences students’ p
Externí odkaz:
https://doaj.org/article/4876ae280f2a4584aae12efebaacc95f
Autor:
Monika Baier, Elizabeth Fisher, N. A. Simonian, Bianca Weinstock-Guttman, Deborah M. Miller, Richard A. Rudick, Michele Mass, Gary Cutter, David S Doughtery
Publikováno v:
Multiple Sclerosis Journal. 9:1-5
Health-Related Q uality of Life (HRQ oL) research is gaining acceptance in the field of multiple sclerosis (MS). Little is known about what precipitates quality of life change. It was hypothesized that physical aspects of quality of life decline with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01f111a4dec9b186be883361a754606c
https://doi.org/10.1191/1352458503ms888oa
https://doi.org/10.1191/1352458503ms888oa
Autor:
Elizabeth Fisher, Richard A. Rudick, D. S. Dougherty, Monika Baier, Michele Mass, N. A. Simonian, Jar-Chi Lee, Jack H. Simon, Bianca Weinstock-Guttman, Gary Cutter, David Miller
Publikováno v:
Neurology. 59:1412-1420
Objective: To characterize whole-brain atrophy in relapsing-remitting MS (RRMS) patients over an 8-year period. The specific goals of this study were to determine if brain atrophy is related to subsequent disability status and to identify MRI correla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86937630e0c6555e4d864e22f96bcbcb
https://doi.org/10.1212/01.wnl.0000036271.49066.06
https://doi.org/10.1212/01.wnl.0000036271.49066.06
Autor:
N. A. Simonian, Elizabeth M. C. Fisher, Richard A. Rudick, Michele Mass, Monika Baier, Bianca Weinstock-Guttman, Darin D. Dougherty, DH Miller, Gary Cutter
Publikováno v:
Neurology. 56:1324-1330
Objective: To determine whether the MS Functional Composite (MSFC) can predict future disease progression in patients with relapsing remitting MS (RR-MS). Background: The MSFC was recommended by the Clinical Outcomes Assessment Task Force of the Nati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d2287093ff3503d1dafb593b5fa2fc8
https://doi.org/10.1212/wnl.56.10.1324
https://doi.org/10.1212/wnl.56.10.1324
Autor:
N. A. Simonian, J H Simon, Roy W. Beck, T J Murray, Lawrence Jacobs, Alfred Sandrock, P J Slasor, C. M. Brownscheidle, R. P. Kinkel
Publikováno v:
New England Journal of Medicine. 343:898-904
Background Treatment with interferon beta has been shown to help patients with established multiple sclerosis, but it is not known whether initiating treatment at the time of a first clinical demyelinating event is of value. Methods We conducted a ra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d2fe5afbffdc39a928d63a61a89c20be
https://doi.org/10.1056/nejm200009283431301
https://doi.org/10.1056/nejm200009283431301
Autor:
N. A. Simonian, Bianca Weinstock-Guttman, John R. Richert, Wendy Jones, Michael E. Coats, Robert M. Herndon, Michele Mass, Richard A. Rudick, Donald E. Goodkin, BK Burnett, James Scaramucci, Emmanuelle Waubant, Lawrence Jacobs
Publikováno v:
International Journal of MS Care. 1:3-11
In a phase III, double-blind, placebo-controlled, 2-year clinical trial, interferon beta-1a (IFN-β-1a, Avonex) treatment significantly delayed disability progression, decreased exacerbations, and reduced brain lesions on magnetic resonance imaging (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::803e859ea194a039d59817c6ea1631c8
https://doi.org/10.7224/1537-2073-1.2.3
https://doi.org/10.7224/1537-2073-1.2.3
Autor:
N. A. Simonian, Kathy O'Reilly, J. S. Fischer, Michele K. Mass, Jonathan Braiman, Lawrence Jacobs, K. E. Wende, Frederick E. Munchsauer, Barbara J. Scherokman, Carol M. Brownscheidle, Carl V. Granger, Robert M. Herndon, David S. Dougherty, David M. Bartoszak, Donald E. Goodkin, John R. Richert, Bianca Weinstock-Guttman, Richard A. Rudick, Roger L. Priore, Andres M. Salazar, Diane Cookfair, Stanley L. Cohan, Ruth H. Whitham, Dennis Bourdette, Michael E. Coats, R. P. Kinkel, Richard M. Ransohoff, Patrick M. Pullicino, Jack H. Simon
Publikováno v:
Journal of Neuroimmunology. 93:8-14
Background and objective : This report provides results of CSF analyses done in a subset of relapsing remitting MS patients participating in a placebo-controlled, double-blind, phase III clinical trial of IFNβ-Studies supported by the National Multi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::694ae9218bef5793925f24d4e27180ff
https://doi.org/10.1016/s0165-5728(98)00174-x
https://doi.org/10.1016/s0165-5728(98)00174-x
Autor:
N. A. Simonian, Andres M. Salazar, Wendy Jones, M. Campion, Bianca Weinstock-Guttman, Michele Mass, J. A. Alam, James Scaramucci, Richard A. Rudick, Donald E. Goodkin, Lawrence Jacobs, John R. Richert, Frederick Munschauer, Diane Cookfair, Robert M. Herndon, Michael E. Coats, Jack H. Simon
Publikováno v:
Neurology. 50:1266-1272
Background: Interferon beta is an effective treatment for relapsing multiple sclerosis(MS). As with other protein drugs, neutralizing antibodies (NAB) can develop that reduce the effectiveness of treatment. Objectives: To determine the incidence and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0f411a2c7d1be7c9271b490b2b7fc4dc
https://doi.org/10.1212/wnl.50.5.1266
https://doi.org/10.1212/wnl.50.5.1266
Autor:
Ann Scherzinger, Bianca Weinstock-Guttman, Frederick Munschauer, Carol M. Brownscheidle, Carl V. Granger, Roger L. Priore, Richard A. Rudick, John J. Alam, Patrick M. Pullicino, Lawrence Jacobs, Jack H. Simon, Robert M. Herndon, Michele Mass, Andres M. Salazar, Jeanelle Sheeder, K. E. Wende, N. A. Simonian, Stanley Cohan, Michelle Lajaunie, David S. Dougherty, Jonathan Braiman, Diane Cookfair, J. S. Fischer, Ruth H. Whitham, Michael E. Coats, Mary Joel Meyer, Donald E. Goodkin, David M. Bartoszak, Kim Choi, Dennis Bourdette, Barbara J. Scherokman, John R. Richert, R. P. Kinkel, Anna L. Martens-Davidson, M. Campion
Publikováno v:
Annals of Neurology. 43:79-87
The Multiple Sclerosis Collaborative Research Group trial was a double-blind, randomized, multicenter, phase III, placebo-controlled study of interferon beta-1a (IFNbeta-1a; AVONEX) in relapsing forms of multiple sclerosis. Initial magnetic resonance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e0e5eab1a6185ca6b61e8aaa1f979845
https://doi.org/10.1002/ana.410430114
https://doi.org/10.1002/ana.410430114
Autor:
R. H. Whitham, D. S. Dougherty, P. M. Pullicino, David M. Bartoszak, Michael E. Coats, J. S. Fischer, Jack H. Simon, C. M. Brownscheidle, L. D. Jacobs, Richard A. Rudick, B. Weistock-Guttman, N. A. Simonian, B. J. Scherokman, J. R. Richert, C. V. Granger, Robert M. Herndon, Michele Mass, D. L. Cookfair, Andres M. Salazar, R. L. Priore, J. J. Alam, R. P. Kinkel, Dennis Bourdette, F. E. Munschauer, Jonathan Braiman, S. L. Cohan, Donald E. Goodkin, M. K. Campion
Publikováno v:
Neurology. 49:358-363
Background and Objective: A phase III double-blind, placebo-controlled clinical trial demonstrated that interferon beta-la (IFNβ-1a) (Avonex, Biogen) significantly delayed progression of disability in relapsing MS patients. The primary clinical outc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e29bb515d0eef4fe10f80d9ae4105c35
https://doi.org/10.1212/wnl.49.2.358
https://doi.org/10.1212/wnl.49.2.358